Regulatory-affairs lead must resolve whether a CMC change is a comparability

Situation

In a mid-size sponsor after a complete response letter, scientific-advice briefing book is the evidence after a site-change that invalidates stability claims. Regulatory-affairs lead has to pick A CMC change is a comparability or A new product for this Pharma & Life Sciences FDA Response and Labeling close using scientific-advice briefing book.

Decision

Regulatory-affairs lead in a mid-size sponsor after a complete response letter must choose A CMC change is a comparability / A new product using scientific-advice briefing book after a site-change that invalidates stability claims.

Hypotheses to test

• Authorize A CMC change is a comparability now; scientific-advice briefing book already has the discriminator after a site-change that invalidates stability claims.
• Keep A new product in force until scientific-advice briefing book is completed after a site-change that invalidates stability claims for regulatory-affairs lead.
• Treat scientific-advice briefing book as A CMC change is a comparability because both readings appear after a site-change that invalidates stability claims.
• Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the page a CMC change is turns on in scientific-advice briefing book.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether scientific-advice briefing book supports the labeled claim regulatory-affairs lead would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• For this Pharma & Life Sciences FDA Response and Labeling file, read scientific-advice briefing book against a site-change that invalidates stability claims and write the one fact that would move a CMC change is for regulatory-affairs lead.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / FDA Response and Labeling packet (scientific-advice briefing book after a site-change that invalidates stability claims). If scientific-advice briefing book cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent pages a mid-size sponsor after a complete response letter does not have.